A Phase III Randomized Trial of Eribulin NSC 707389 with Gemcitabine Versus Standard of Care Physician's Choice for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy

Brief Summary

Type:
Bladder

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT04579224

Study #:
STUDY00149761

Start Date:
Mar 23, 2023

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT04579224

View Complete Trial Details & Eligibility at ClinicalTrials.gov